Context Therapeutics Inc.

What they do

Context Therapeutics is a clinical-stage biopharmaceutical company focused on advancing T cell engaging (TCE) bispecific antibodies (bsAb) for solid tumors. Its pipeline includes CTIM-76 (CLDN6 x CD3 TCE), CT-202 (Nectin-4 x CD3 TCE), and previously CT-95 (MSLN x CD3 TCE) which was discontinued in August 2026. The company operates as one business segment and has not generated any product revenue.

Revenue drivers

• CTIM-76 (CLDN6 x CD3 TCE) — Lead clinical candidate in Phase 1 for CLDN6-positive gynecologic and testicular cancers; received FDA Fast Track designation for platinum-resistant ovarian cancer in April 2026; no revenue yet.
• CT-202 (Nectin-4 x CD3 TCE) — Preclinical/early clinical candidate targeting Nectin-4-positive tumors; IND cleared in Australia (April 2026); first patient dosing expected Q3 2026; no revenue yet.
• CT-95 (MSLN x CD3 TCE) — Discontinued internal development in August 2026; Phase 1 trial being wound down; no revenue generated.

Recent performance

For the six months ended June 30, 2026, the company reported a net loss of $23.2 million and an accumulated deficit of $154.1 million. As of June 30, 2026, cash and equivalents were $43.0 million, total assets $46.1 million, total liabilities $8.0 million, and shareholder equity $38.2 million. Annual net losses have increased from $10.5 million in 2021 to $36.1 million in 2025. Operating cash flow was negative $26.4 million in 2025 and negative $14.6 million in 2024. No revenue has been generated from product sales.

Strategy

Management is prioritizing CTIM-76 and CT-202, discontinuing CT-95 to focus resources. CTIM-76 is advancing into Q3W dosing in less heavily pretreated platinum-resistant ovarian cancer patients in H2 2026, with Phase 1b dose expansion expected to start Q1 2027. CT-202 is expected to dose first patient in Q3 2026, with initial Phase 1a data expected in H2 2027. The company also plans to evaluate opportunities to expand its TCE pipeline and may seek partnerships to accelerate development and commercialization.

Risks

• No profitability — The company has never been profitable and expects to continue incurring significant operating losses.
• Need for additional capital — Substantial additional funding will be required; if not raised on acceptable terms, development may be delayed or terminated.
• Clinical-stage risk — All product candidates are in early-stage trials; interim data may not be indicative of final results, and safety issues could halt development.
• Patient enrollment and regulatory delays — Difficulty enrolling patients or receiving regulatory approvals could delay or prevent clinical progress and potential commercialization.

Outlook

Management expects to share initial Phase 1a data for CTIM-76 Q3W trial in Q2 2027 and for CT-202 in H2 2027. Initiation of CTIM-76 Phase 1b dose expansion is anticipated in Q1 2027. CT-95 trial is being wound down, with resources redirected to CTIM-76 and CT-202.